Literature DB >> 10959051

Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation.

G U Dachs1, G M Tozer.   

Abstract

Tumour hypoxia is the result of an imbalance in oxygen supply and demand. It is an adverse prognostic indicator in cancer as it modulates tumour progression and treatment. Many genes controlling tumour biology are oxygen regulated, and new ones are constantly added to the growing list of hypoxia-induced genes. Of specific importance are hypoxia-responsive transcription factors, as they can modulate the expression of numerous different genes. Similarly, growth factors which govern the formation of new blood vessels or which control blood flow are vitally important for both the maintenance of the primary tumour and metastases at distant sites. The purpose of this review is to present an update of selected issues regarding hypoxia-inducible gene expression and how this affects prognosis, angiogenesis and metastasis. It will conclude by discussing gene therapy as one possible means of exploiting tumour hypoxia for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10959051     DOI: 10.1016/s0959-8049(00)00159-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  57 in total

Review 1.  Physiological and pathological responses to hypoxia.

Authors:  Carine Michiels
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

Review 2.  Review of treatment assessment using DCE-MRI in breast cancer radiation therapy.

Authors:  Chun-Hao Wang; Fang-Fang Yin; Janet Horton; Zheng Chang
Journal:  World J Methodol       Date:  2014-06-26

3.  In vitro antimetastatic effect of Changweiqing through antiinvasion of hypoxic colorectal carcinoma LoVo cells.

Authors:  Jing Li; Zhong-Ze Fan; Jue Sun; Jian-Hua Xu
Journal:  Chin J Integr Med       Date:  2011-07-03       Impact factor: 1.978

4.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Authors:  Vesselina G Cooke; Valerie S LeBleu; Doruk Keskin; Zainab Khan; Joyce T O'Connell; Yingqi Teng; Michael B Duncan; Liang Xie; Genta Maeda; Sylvia Vong; Hikaru Sugimoto; Rafael M Rocha; Aline Damascena; Ricardo R Brentani; Raghu Kalluri
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

5.  HEXIM1 down-regulates hypoxia-inducible factor-1α protein stability.

Authors:  I-Ju Yeh; Ndiya Ogba; Heather Bensigner; Scott M Welford; Monica M Montano
Journal:  Biochem J       Date:  2013-12-01       Impact factor: 3.857

6.  The translation initiation factor eIF3i up-regulates vascular endothelial growth factor A, accelerates cell proliferation, and promotes angiogenesis in embryonic development and tumorigenesis.

Authors:  Yike Yuan; Yaguang Zhang; Shaohua Yao; Huashan Shi; Xi Huang; Yuhao Li; Yuquan Wei; Shuo Lin
Journal:  J Biol Chem       Date:  2014-08-21       Impact factor: 5.157

7.  Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features.

Authors:  Mireia Crispin-Ortuzar; Aditya Apte; Milan Grkovski; Jung Hun Oh; Nancy Y Lee; Heiko Schöder; John L Humm; Joseph O Deasy
Journal:  Radiother Oncol       Date:  2017-12-19       Impact factor: 6.280

8.  Tumor-specific gene expression using the survivin promoter is further increased by hypoxia.

Authors:  L Yang; Z Cao; F Li; D E Post; E G Van Meir; H Zhong; W C Wood
Journal:  Gene Ther       Date:  2004-08       Impact factor: 5.250

9.  Biomolecular markers in cancer of the tongue.

Authors:  Daris Ferrari; Carla Codecà; Jessica Fiore; Laura Moneghini; Silvano Bosari; Paolo Foa
Journal:  J Oncol       Date:  2009-08-19       Impact factor: 4.375

10.  Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia.

Authors:  O Thews; T Wolloscheck; W Dillenburg; S Kraus; D K Kelleher; M A Konerding; P Vaupel
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.